← Back to Clinical Trials
Recruiting NCT06940622

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Recurrent UTIs
Sponsor University of Texas Southwestern Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 90
Sex FEMALE
Min Age 55 Years
Max Age 85 Years
Start Date 2025-08-01
Completion 2029-09-30
Interventions
D-MannosePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.

Eligibility Criteria

Inclusion Criteria: * Female, post-menopausal, age ≥ 55 years old * Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months. * Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\<103 colony forming units per ml of urine). * Able to attend all follow-up appointments for the study. * A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum. Exclusion Criteria: * Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period. * Complicated UTIs, including need for catheter drainage or intermittent

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}